Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03310619
Title A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene

B-cell lymphoma

mediastinal malignant lymphoma


Durvalumab + Lisocabtagene maraleucel

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.